With millions now getting GLP-1 care online, U.S. News sizes up the telehealth services competing in this fast-growing market.
Recap by typeshit. Full story at U.S. News & World Report.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Demócrata reports Lilly's oral GLP-1 met cardiovascular safety and lowered blood sugar and weight in type 2 diabetes. Few details beyond the headline.
The obesity medicine specialist says weight on the scale is only part of the picture when someone is taking a GLP-1 medication.
Loading…